• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Hims & Hers Health Inc. (Amendment)

    2/14/24 4:19:29 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care
    Get the next $HIMS alert in real time by email
    SC 13G/A 1 hims13ga.htm



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549



    SCHEDULE 13G
    (Rule 13d-102)
    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT
    TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED
    PURSUANT TO § 240.13d-2.
    (Amendment No. 3)*


    Hims & Hers Health, Inc.
    (Name of Issuer)
     
    Class A Common Stock, $0.0001 par value per share
    (Title of Class of Securities)
     
    433000 106
    (CUSIP Number)
     
    December 31, 2023
    (Date of Event Which Requires Filing of this Statement)

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     
    ☐
    Rule 13d-1(b)
     
    ☒
    Rule 13d-1(c)
     
    ☐
    Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).



    CUSIP NO.
    433000 106

     
     
                        See response in row 7.
    1
    NAMES OF REPORTING PERSONS
     
     
     
    Jack Abraham
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
     
    (a) ☐  
    (b) ☒ 
    3
    SEC USE ONLY
     
     
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    United States
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
    9,324,3961
     
     
    6
    SHARED VOTING POWER
     
     
    7
    SOLE DISPOSITIVE POWER
     
    9,324,3961
     
     
    8
    SHARED DISPOSITIVE POWER
     
     
     
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    9,324,3961
     
     
    10
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
      ☐
              
     
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    4.6%2
     
     
    12
    TYPE OF REPORTING PERSON*
     
    IN
     
     

    1
    Consists of (i) 68,475 shares of Class A Common Stock held by Atomic Incentives, LLC (“Incentives”), (ii) 319,693 shares of Class A Common Stock held by Atomic Labs I, L.P. (“Labs I”), (iii) 238,967 shares of Class A Common Stock held by Atomic Labs I-B, L.P. (“Labs I-B”), (iv) 4,039,801 shares of Class A Common Stock held by The Jack Abraham Living Trust (“Living Trust”), (v) 2,541,558 shares of Class A Common Stock held by The Jack Abraham 2020 Irrevocable Trust A (“Abraham Trust”), (vi) 55,206 shares of Class A Common Stock held by Atomic GP II, LLC (“Atomic GP II”), (vii) 2,030,303 shares of Class A Common Stock held by Atomic Labs II L.P. (“Labs II”) and (viii) 30,393 shares of Class A Common Stock held by Atomic Labs, LLC (“Labs LLC”). Mr. Abraham is the sole manager of Labs LLC, which is the sole member of Incentives and, as such, may be deemed to hold voting and dispositive power with respect to the securities held by Labs LLC and Incentives. Mr. Abraham is the sole managing member of Atomic Labs GP I, LLC, which is the general partner of Labs I and Labs I-B and, as such, may be deemed to hold voting and dispositive power with respect to the securities held by Labs I and Labs I-B. Mr. Abraham may be deemed to hold voting and dispositive power with respect to the securities held by Living Trust. Mr. Abraham may be deemed to hold voting and dispositive power with respect to the securities held by Abraham Trust. Mr. Abraham is a managing member of Atomic GP II and, as such, may be deemed to hold voting and dispositive power with respect to the securities it holds. Mr. Abraham is a managing member of Atomic GP II, which is the general partner of Labs II and, as such, may be deemed to hold voting and dispositive power with respect to the securities held by Labs II. The Reporting Person disclaims the existence of a "group" and disclaims beneficial ownership of such securities held by entities affiliated with him except to the extent of his indirect pecuniary interest therein, if any.

    2
    The percentage calculation is based on a total of 203,615,885 shares of Class A Common Stock outstanding as of November 3, 2023, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 6, 2023.

    CUSIP NO.
    433000 106

     
     
     
    Item 1(a)
    Name of Issuer:
     
     
     
    Hims & Hers Health, Inc. (the “Issuer”)
     
     
    Item 1(b)
    Address of Issuer's Principal Executive Offices:
     
     
     
    2269 Chestnut Street, #523, San Francisco, California 94123
     
     
    Item 2(a)
    Name of Person Filing:
     
     
     
    Jack Abraham
     
     
    Item 2(b)
    Address of Principal Business Office or, if none, Residence:
     
     
     
    c/o Atomic Labs, LLC, 215 NW 24th Street, Suite 400, Miami, FL 33127
     
     
    Item 2(c)  Citizenship:
     
     
    See Row 4 of cover page for the Reporting Person
     

    Item 2(d)
    Title of Class of Securities:
     
     
     
    Class A Common Stock, par value $0.0001 (“Class A Common Stock”)
     
     
    Item 2(e)
    CUSIP No.:
     
     
     
    433000 106
     
     
    Item 3
    If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b), check whether the person filing is a:
     
     
     
    Not applicable.
     
     
    Item 4
    Ownership:
     
     
     
    The following information with respect to the ownership of the Class A Common Stock of the Issuer by the person filing this Statement is provided as of December 31, 2023:

     
    (a)
      Amount beneficially owned: See Row 9 of cover page for the Reporting Person.

     
    (b)
      Percent of class:  See Row 11 of cover page for the Reporting Person.
     
     
    (c)
      Number of shares as to which such person has: 
     
     
    (i)
      Sole power to vote or direct the vote:  See Row 5 of cover page for the Reporting Person.
     
     
     
    (ii)
      Shared power to vote or direct the vote: See Row 6 of cover page for the Reporting Person.
     
     
     
    (iii)
      Sole power to dispose or direct the disposition:  See Row 7 of cover page for the Reporting Person.
     
     
     
    (iv)
      Shared power to dispose or direct the disposition: See Row 8 of cover page for the Reporting Person.
     
     

    Item 5
    Ownership of Five Percent or Less of a Class:
     
     
     
    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☒.
     
     
    Item 6
    Ownership of More Than Five Percent on Behalf of Another Person:
     
     
     
    Not applicable.
     
     
    Item 7
    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person:
     
     
     
    Not applicable.
     
     
    Item 8
    Identification and Classification of Members of the Group:
     
     
     
    Not applicable.
     
     
    Item 9
    Notice of Dissolution of Group:
     
     
     
    Not applicable.
     
     
    Item 10
    Certification:
     
     

    By signing below, I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
     
     
     

    CUSIP NO.
    433000 106

     
     

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this Schedule 13G is true, complete and correct.

    Date: February 14, 2024


     

     
     JACK ABRAHAM
     
     
     
     
     
       
     



     
     By:  /s/ Jack Abraham
     



     
     Name:  Jack Abraham
     




    Get the next $HIMS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $HIMS

    DatePrice TargetRatingAnalyst
    3/10/2026$24.00Sell → Neutral
    Citigroup
    3/10/2026$23.00Underperform → Neutral
    BofA Securities
    3/9/2026$30.00Hold → Buy
    Needham
    2/24/2026Buy → Neutral
    BTIG Research
    1/12/2026$33.00In-line
    Evercore ISI
    12/9/2025$48.00Overweight
    Barclays
    10/21/2025Sector Weight
    KeyBanc Capital Markets
    6/23/2025Buy → Hold
    Needham
    More analyst ratings

    $HIMS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Becklund Irene

    4 - Hims & Hers Health, Inc. (0001773751) (Issuer)

    3/18/26 4:17:47 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    SEC Form 4 filed by Chi Michael

    4 - Hims & Hers Health, Inc. (0001773751) (Issuer)

    3/18/26 4:17:34 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    SEC Form 4 filed by Boughton Soleil

    4 - Hims & Hers Health, Inc. (0001773751) (Issuer)

    3/18/26 4:17:40 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    $HIMS
    SEC Filings

    View All

    SEC Form 8-K filed by Hims & Hers Health Inc.

    8-K - Hims & Hers Health, Inc. (0001773751) (Filer)

    3/11/26 5:21:18 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Hims & Hers Health Inc.

    SCHEDULE 13G/A - Hims & Hers Health, Inc. (0001773751) (Subject)

    3/5/26 11:49:35 AM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    SEC Form S-8 filed by Hims & Hers Health Inc.

    S-8 - Hims & Hers Health, Inc. (0001773751) (Filer)

    2/24/26 4:34:53 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    $HIMS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Hims & Hers Names Kathryn Beiser as Chief Communications Officer

    The global communications leader, who previously held roles at Eli Lilly and Kaiser Permanente, joins the world's leading consumer health platform in its next phase of growth Hims & Hers Health, Inc. (NYSE:HIMS), the leading global health and wellness platform, today announced the appointment of Kathryn Beiser as Chief Communications Officer. In this role, Beiser will lead external and internal communications for the company as it enters a new phase of domestic and international growth. In her role as CCO, Beiser will report to CEO Andrew Dudum and focus on continuing to build the Hims & Hers brand and reputation while helping the industry understand the company's expansive vision for the

    3/10/26 8:08:00 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Introducing Hims & Hers Benefits, Unlocking Health & Wellness Discounts for Subscribers

    The program debuts with Prenuvo and Eight Sleep, providing discounts on advanced diagnostics and sleep technology Hims & Hers Health, Inc. (NYSE:HIMS), the leading health and wellness platform, today announced Hims & Hers Benefits, a new way for subscribers to access the best innovations in whole body health. This new initiative provides active subscribers access to discounts from health partners, all in one place, including whole body MRI scans from Prenuvo and adaptive bed systems from Eight Sleep. This is just the beginning of a larger benefits program that will make comprehensive, holistic care more accessible and affordable for subscribers. "True health doesn't happen in a vacuum.

    3/10/26 9:00:00 AM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Hims & Hers Announces Strategic Shift for US Weight Loss Business

    Starting with a new collaboration with Novo Nordisk, the company announced plans to align its US and global strategies with a focus on an increasing variety of FDA-approved GLP-1s Hims & Hers Health, Inc. (NYSE:HIMS) today announced a collaboration with Novo Nordisk as part of a new strategy for weight loss care treatments involving GLP-1s, evolving its US offering to match the company's approach globally. In the US, the company now plans to provide GLP-1 customers with access to a broad assortment of FDA-approved medications and offer compounded semaglutide through the platform on a limited scale. By aligning its domestic and international models in weight loss, Hims & Hers will become t

    3/9/26 8:30:00 AM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    $HIMS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Hims & Hers Health upgraded by Citigroup with a new price target

    Citigroup upgraded Hims & Hers Health from Sell to Neutral and set a new price target of $24.00

    3/10/26 8:37:35 AM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Hims & Hers Health upgraded by BofA Securities with a new price target

    BofA Securities upgraded Hims & Hers Health from Underperform to Neutral and set a new price target of $23.00

    3/10/26 8:37:14 AM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Hims & Hers Health upgraded by Needham with a new price target

    Needham upgraded Hims & Hers Health from Hold to Buy and set a new price target of $30.00

    3/9/26 11:28:34 AM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    $HIMS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Manuel Anja bought $132,260 worth of shares (5,000 units at $26.45) (SEC Form 4)

    4 - Hims & Hers Health, Inc. (0001773751) (Issuer)

    11/14/24 4:57:45 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Payne Christopher D bought $1,951,763 worth of shares (110,000 units at $17.74) (SEC Form 4)

    4 - Hims & Hers Health, Inc. (0001773751) (Issuer)

    5/22/24 4:16:26 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    $HIMS
    Leadership Updates

    Live Leadership Updates

    View All

    Hims & Hers Names Kathryn Beiser as Chief Communications Officer

    The global communications leader, who previously held roles at Eli Lilly and Kaiser Permanente, joins the world's leading consumer health platform in its next phase of growth Hims & Hers Health, Inc. (NYSE:HIMS), the leading global health and wellness platform, today announced the appointment of Kathryn Beiser as Chief Communications Officer. In this role, Beiser will lead external and internal communications for the company as it enters a new phase of domestic and international growth. In her role as CCO, Beiser will report to CEO Andrew Dudum and focus on continuing to build the Hims & Hers brand and reputation while helping the industry understand the company's expansive vision for the

    3/10/26 8:08:00 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Hims & Hers Announces Agreement to Acquire Eucalyptus, Accelerating Its Vision to Become the Leading Global Consumer Health Platform

    Eucalyptus is a consumer healthcare leader in Australia, the UK and Germany, with expanding new operations in Japan and Canada. Hims & Hers Health, Inc. (NYSE:HIMS), the leading health and wellness platform, today announced it has entered into a definitive agreement to acquire Eucalyptus, an international leader in digital health, accelerating the company's ability to bring access to high-quality, personalized care to more people across the world. As its US business continues to grow, Hims & Hers will be well-positioned, upon closing of the acquisition, to expand into Australia and Japan and deepen its presence in the UK, Germany, and Canada. The terms of the transaction have been structu

    2/19/26 6:00:00 AM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Hims & Hers Names Deb Autor as Chief Policy Officer to Lead Global Policy and Regulatory Strategy

    Hims & Hers Health, Inc. (NYSE:HIMS), the leading health and wellness platform, today announced the appointment of Deb Autor as the company's first Chief Policy Officer. In this new role, Autor will collaborate with other stakeholders, including consumers, telehealth platforms, providers, advocacy groups, medical associations, pharmaceutical companies, medtech innovators, policymakers, and regulators, with the goal of paving the way to the healthcare of the future - where the power of technology will be combined with the best of personalized care. She will lead the company's global public policy, regulatory, and government affairs functions. A former senior leader at the FDA, prosecutor f

    11/17/25 6:00:00 AM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    $HIMS
    Financials

    Live finance-specific insights

    View All

    Hims & Hers Health, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results

    Revenue of approximately $2.35 billion, up 59% year-over-year in 2025 Net income of $128 million; Adjusted EBITDA of $318 million in 2025 Subscribers grew to over 2.5 million, up 13% year-over-year in 2025 Provides Q1 and full year 2026 guidance1, with full year 2026 revenue in the range of $2.7 billion to $2.9 billion and Adjusted EBITDA in the range of $300 million to $375 million Hims & Hers Health, Inc. (("Hims &, Hers" or the "Company", NYSE:HIMS), the leading health and wellness platform, today announced financial results for the fourth quarter and full year ended December 31, 2025 in a shareholder letter that is posted at investors.hims.com. "More than 2.5 million subscribe

    2/23/26 4:05:00 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Hims & Hers to Announce Fourth Quarter and Full Year 2025 Financial Results on February 23, 2026

    Hims & Hers Health, Inc. (("Hims &, Hers", NYSE:HIMS), the leading health and wellness platform, today announced that it will report fourth quarter and full year 2025 financial results after the market closes on Monday, February 23, 2026. The company will host a live conference call to discuss the results at 5:00 p.m. ET the same day. The conference call can be accessed by dialing (888) 510-2630 for U.S. participants and (646) 960-0137 for international participants, referencing conference ID 1704296. A live audio webcast will be available at https://investors.hims.com and will be archived for one year. Upcoming Conference Participation Hims & Hers also announced that members of the c

    2/2/26 4:05:00 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Hims & Hers Health, Inc. Reports Third Quarter 2025 Financial Results

    Revenue of nearly $600 million, up 49% year-over-year in Q3 2025 Net income of nearly $16 million; Adjusted EBITDA of over $78 million in Q3 2025 Subscribers grew to almost 2.5 million, up 21% year-over-year in Q3 2025 Narrows full year 2025 revenue guidance to $2.335 billion to $2.355 billion and Adjusted EBITDA guidance to $307 million to $317 million Hims & Hers Health, Inc. (("Hims &, Hers" or the "Company", NYSE:HIMS), the leading health and wellness platform, today announced financial results for the third quarter ended September 30, 2025, in a shareholder letter that is posted at investors.hims.com. "This quarter we continued to prove that our vision of helping tens of mill

    11/3/25 4:05:00 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    $HIMS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Hims & Hers Health Inc.

    SC 13G/A - Hims & Hers Health, Inc. (0001773751) (Subject)

    11/12/24 3:52:47 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Amendment: SEC Form SC 13G/A filed by Hims & Hers Health Inc.

    SC 13G/A - Hims & Hers Health, Inc. (0001773751) (Subject)

    11/4/24 1:33:02 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Amendment: SEC Form SC 13G/A filed by Hims & Hers Health Inc.

    SC 13G/A - Hims & Hers Health, Inc. (0001773751) (Subject)

    11/4/24 12:09:24 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care